Roughly 16 million American adults are taking GLP-1 medications. They are a major breakthrough for people to shed pounds and ...

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS ) securities between April 29, 2025 and June 23, 2025, both dates ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

NEW YORK >> More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from ...

Albertsons CEO Susan Morris said she had to "double-check the numbers" when she saw how much cottage cheese the chain was selling.

In an echo of the pattern laid last year, following a record-high outlay at the very beginning of the year, TV drug ad ...

More than half of large employers plan to scale back health care benefits next year as rising costs from weight-loss and specialty drugs squeeze budgets, according to a new survey released by ...

Biocon aims to introduce generic versions of the obesity drug Wegovy in India and Canada by late 2026 or early 2027, ...

Novo Nordisk reportedly failed to pay its annual fees to maintain the patent rights in Canada, opening the door to cheaper ...

Key Points Hims & Hers Health is entering the Canadian market.The company will offer a generic version of semaglutide in the ...

Hims & Hers (HIMS) stock in focus as the company faces a growing number of lawsuits following Novo Nordisk's (NVO) decision ...

Biocon plans to introduce generic versions of the weight-loss drug Wegovy in India and Canada by 2027, according to CEO Siddharth Mittal.